{"id":"W3088144056","doi":"10.1016/j.annonc.2020.08.2282","title":"LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Crizotinib; Medicine; Internal medicine; Interim analysis; Lung cancer; Clinical endpoint; ALK inhibitor; Oncology; Discontinuation; Adverse effect; Progression-free survival; Randomized controlled trial; Overall survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009958972,0.0008928605,0.001909802,0.0002324892,0.0002355997,0.0009711268,0.0006274612,0.0007494457,0.002477853],"category_scores_gemma":[0.0009616191,0.000322938,0.0015335,0.0003274819,0.0004939799,0.0007171308,0.0002984492,0.002553712,0.0005787842],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001168575,"about_ca_system_score_gemma":0.001163631,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003006758,"about_ca_topic_score_gemma":0.01058649,"domain_scores_codex":[0.9996786,0.0001734523,0.00001403751,0.00004271844,0.00002767474,0.00006351041],"domain_scores_gemma":[0.9995275,0.0001128614,0.0001115148,0.00002786121,0.00002623861,0.0001941406],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.876597,0.006972838,0.005536196,0.0007921009,0.002325663,0.00009679881,0.0001021841,0.002054536,0.01109324,0.0002045199,0.004986122,0.0892389],"study_design_scores_gemma":[0.7322981,0.204026,0.04635876,0.0001095615,0.002975787,0.0003871876,0.0001647312,0.003074755,0.002701651,0.0003121733,0.007521747,0.00006946508],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9864874,0.007607706,0.0001658747,0.0009725793,0.0001778472,0.0003039664,0.001470736,0.00009246505,0.002721302],"genre_scores_gemma":[0.9882046,0.004482353,0.0005660708,0.0008368259,0.0002112577,0.0002769591,0.002738863,0.0000332534,0.00264985],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003006758,"threshold_uncertainty_score":0.008478701,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04310889108180626,"score_gpt":0.4027122095319315,"score_spread":0.3596033184501252,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}